Thrombolytic Effects of the Snake Venom Disintegrin Saxatilin Determined by Novel Assessment Methods: A FeCl3-Induced Thrombosis Model in Mice. by 媛뺤꽦�닔 et al.
Thrombolytic Effects of the Snake Venom Disintegrin
Saxatilin Determined by Novel Assessment Methods: A
FeCl3-Induced Thrombosis Model in Mice
Il Kwon1,2,3☯, Sung-Yu Hong2,4☯, Young Dae Kim1,2, Hyo Suk Nam1,2, Sungsoo Kang2,4, Seung-Hee Yang1,2,
Ji Hoe Heo1,2,3*
1 Department of Neurology, Yonsei University College of Medicine, Seoul, Korea, 2 Severance Integrative Research Institute for Cerebral and Cardiovascular
Diseases, Yonsei University College of Medicine, Seoul, Korea, 3 Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea,
4 Cardiovascular Product Evaluation Center, Yonsei University College of Medicine, Seoul, Korea
Abstract
Saxatilin, a novel disintegrin purified and cloned from the venom of the Korean snake Gloydius saxatilis, strongly
inhibits activation and aggregation of platelets. Glycoprotein (GP) IIb/IIIa receptor antagonists can resolve thrombus,
so saxatilin might also have thrombolytic effects. We investigated the thrombolytic effects of saxatilin in mice using a
ferric chloride-induced carotid arterial thrombosis model. Thrombotic occlusion and thrombus resolution were
evaluated quantitatively by measuring blood flow in the carotid artery with an ultrasonic flow meter and calculating the
degree of flow restoration on a minute-by-minute basis; results were confirmed by histological examination. Saxatilin
dissolved thrombi in a dose-dependent manner. Saxatilin at 5 mg/kg restored blood flow to baseline levels. As
saxatilin dose increased, time to recanalization decreased. A bolus injection of 10% of a complete dose with
continuous infusion of the remaining dose for 60 minutes resulted in effective recanalization without reocclusion. The
thrombolytic effect of saxatilin was also demonstrated in vitro using platelet aggregometry by administering saxatilin
in preformed thrombi. Bleeding complications were observed in 2 of 71 mice that received saxatilin. Fibrin/fibrinogen
zymography and platelet aggregometry studies indicated that saxatilin does not have fibrinolytic activity, but exerted
its action on platelets. Integrin-binding assays showed that saxatilin inhibited multiple integrins, specifically α2bβ3 (GP
IIb/IIIa), α5β1, αvβ3, αvβ1, and αvβ5, which act on platelet adhesion/aggregation. Saxatilin inhibited multiple integrins by
acting on platelets, and was safe and effective in resolving thrombi in mice.
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Introduction
Intravenous (IV) administration of recombinant tissue
plasminogen activator (rt-PA) is an effective treatment for
ischemic strokes if administered within 4.5 hours of symptom
onset [1,2]. However, more than two-thirds of patients fail to
achieve successful recanalization after IV rt-PA treatment [3,4].
rt-PA also has neurotoxic effects [5]. To improve thrombolytic
potency and to reduce the potential adverse effects of rt-PA,
several new thrombolytic agents have been developed. They
include variants of t-PA, and microplasmin, plasmin, and
plasminogen activators from animal sources [6-9]. The goal of
new thrombolytic drugs is enhanced fibrin specificity, extended
plasma half-life, reduced inhibition by plasminogen activator
inhibitor-1, and no neurotoxicity [10]. While new drugs target
the fibrin component of thrombi, thrombi are formed by platelet-
fibrinogen interaction. Resistance of platelet-rich thrombi to
thrombolytic agents that target fibrin is a primary cause of
thrombolysis failure. For this reason, treatments that target
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platelets might be useful since disaggregation of platelets from
fibrin is a potential approach for dissolving thrombi [11,12].
Adhesion and aggregation of platelets are mediated by
interactions of ligands with multiple integrins, including integrins
α2bβ3 (glycoprotein [GP] IIb/IIIa), α2β1, α5β1, and αvβ3. Among
these integrins, the GP IIb/IIIa receptor, which mediates the
final common pathway of platelet aggregation by binding
specifically to fibrinogen [13], is the main target of drugs
developed to act against platelets. Several platelet GP IIb/IIIa
receptor antagonists have been developed, including the Fab
fragment of a human-mouse chimeric antibody against GP IIb/
IIIa (abciximab), nonpeptide analogs of an Arg-Gly-Asp (RGD)
peptide (tirofiban and lamifiban), and a cyclic heptapeptide
disintegrin containing a Lys-Gly-Asp (KGD) motif (eptifibatide)
[14-16]. These GP IIb/IIIa antagonists have been effective at
resolving thrombi by dethrombotic mechanisms (disaggregation
of platelets bound to fibrinogen) in selected patients with acute
coronary syndrome or stroke [14,15,17-19].
Saxatilin, a novel disintegrin purified and cloned from the
venom of the Korean snake Gloydius saxatilis, has the
tripeptide sequence RGD [20,21]. Saxatilin has a molecular
mass of 7712 Da, and strongly inhibits platelet activation [22]
and platelet aggregation [21]. Considering the known effects of
GP IIb/IIIa receptor inhibitors on thrombus resolution, saxatilin
might possess thrombolytic effects. In this study, the effect of
IV saxatilin on thrombus resolution was examined using a ferric
chloride (FeCl3)-induced arterial thrombosis model in mice and
platelet aggregometry [23,24]. We also introduced novel
analytic measures to quantitate thrombolytic effects using
FeCl3-induced arterial thrombosis model and platelet
aggregometry.
Materials and Methods
Ethics Statement
All animal procedures were reviewed and approved by the
Institutional Animal Care and Use Committee (IACUC) of
Yonsei University College of Medicine (approval number:
2010-0268) and were performed in strict accordance with the
Association for Assessment and Accreditation of Laboratory
Animal Care (AAALAC).
Experimental animals and FeCl3-induced carotid artery
thrombosis
Eight-week-old male Institute of Cancer Research (ICR) mice
weighing 32-34 g were used. Animals were housed in a
temperature-controlled animal facility under a 12/12 hours
reversed light and dark cycle, in a plastic cage with soft
bedding, and given with a free access to food and water. For
operative procedures, animals were anesthetized with 5%
isoflurane in a mixture of 70% N2O and 30% O2. Anesthesia
was maintained with 2% isoflurane. During operative
procedures, body temperature was monitored continuously with
a rectal probe and maintained at 37.0 ± 0.2°C using a
homeothermic blanket control unit and a heating pad (Harvard
Apparatus, Holliston, MA, USA). A FeCl3-induced carotid
thrombosis model was used to test the thrombolytic activity of
saxatilin in vivo. A midline cervical incision was made, and the
left common carotid artery was carefully dissected under a
surgical microscope. An ultrasonic Doppler ﬂow probe
(MA0.7PSB; Transonic Instruments, Ithaca, NY, USA) was
placed around midportion of the common carotid artery (CCA).
Carotid blood flow was obtained with a Transonic TS420 Blood
Flow Meter (Transonic Instruments, Ithaca, NY, USA) and an
iWorx IX-304T data acquisition system (iWorx Systems, Inc.,
Dover, NH). Computer-based analysis by iWorx Labscribe 2
software (version 2.045000) was performed to minimize any
bias when assessing results. CCA baseline flow was measured
for 5 minutes. Oxidative vascular injury with chemical stress
was induced by placing a filter paper (700 μm × 500 μm)
saturated with 50% FeCl3 (F2877; Sigma-Aldrich Inc., St. Louis,
MO, USA) on the adventitial surface of the midpoint of the
exposed CCA for 5 minutes. After removing the filter paper, the
CCA was washed with normal saline and blood flow was
recorded. Thrombus formation and arterial occlusion were
determined by decreased blood flow, and complete occlusion
was deﬁned as absence of blood flow for 10 minutes.
Determination of thrombotic occlusion and
measurement of thrombus size
Consistency of the mouse model for thrombus formation and
size was assessed. Ten minutes after complete occlusion,
injured CCA segments were excised, immediately immersed in
4% paraformaldehyde for fixation, and embedded in paraffin for
histological analysis. Paraffin blocks were consecutively
sectioned longitudinally into 3 μm slices. Sectioned slices were
mounted on glass slides and stained with hematoxylin and
eosin. Thrombus size (longitudinal length and area) for each
animal was determined using a light microscope (Axio
Imager.D2; Carl Zeiss Microimaging, Oberkochen, Germany)
and Zeiss AxioVision software (AxioVs40 V 4.8.1.0; Carl Zeiss
imaging Solution) for a slice representing the largest part of the
thrombus.
Electron microscopic examination
For transmission electron microscopy (TEM), arteries were
immediately fixed with Karnovsky solution (pH 7.4, 2%
glutaraldehyde, 2% paraformaldehyde, 0.5% CaCl2) overnight
at 4°C, washed in 0.1 M phosphate buffer (pH 7.4) and post-
fixed in 1% osmium tetroxide in the same buffer for 2 hours.
Specimens were then dehydrated through a series of
ascending ethanol concentrations, exchanged through
propylene oxide, and incubated with a 1:1 mixture of EPON
(EPON 812, MNA, DDSA, DMP 30) and propylene oxide for 18
hours, embedded in an EM oven, and trimmed. Subsequently,
0.25 μm semi-thin sections were stained with toluidine blue and
observed under a light microscope to determine the FeCl3-
damaged region. After retrimming, ultrathin sections (80 nm)
were obtained by ultramicrotome (Ultracut UCT, Leica, Austria)
with a diamond knife, double stained with uranyl acetate and
lead citrate, and examined by TEM (JEOL-1011; JEOL, Japan)
at 80 kV [25].
For scanning electron microscopy (SEM), specimens were
fixed and dehydrated as described above, replaced with
isoamyl acetate, dried in a critical point dryer (HCP-2; Hitachi
Co., Tokyo, Japan), coated with a thin layer of gold (100 nm) in
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an ion coater (IB-3; Eiko engineering, Ibaraki, Japan), and
examined with by field-emission SEM (S-800; Hitachi Co.,
Tokyo, Japan) at 20 kV.
Selection of optimal FeCl3 concentration
To determine the optimal condition of the FeCl3-induced
arterial thrombosis model for evaluation of thrombolytic effects,
10%, 20%, 30%, 40%, and 50% (w/v) concentrations of the
FeCl3 were tested using five mice for each test concentration.
Carotid blood flow was measured continuously for 150 minutes
from complete occlusion.
Intravenous thrombolysis using saxatilin
Expression and mass production of saxatilin have been
described [20,26]. Ten minutes after CCA occlusion, IV
administration of saxatilin was performed via the left femoral
vein with an infusion pump (KDS100 syringe pump; KD
Scientific, Holliston, MA, USA) connected to PE-10 tubing.
Carotid blood flow was continuously monitored for 2 hours from
the initial time of injection.
Dose response to saxatilin.  To evaluate the dose
response to saxatilin, animals were randomly divided into
seven groups, with five mice in each group: normal saline
(control group), 1, 1.75, 2.5, 3.75, 5.0, or 10.0 mg/kg saxatilin.
Ten percent of the dose was administered by IV bolus, and the
rest was infused continuously for 60 minutes.
Methods for administering saxatilin.  The thrombolytic
effects of saxatilin were assessed after different administration
methods. A total dose of 5 mg/kg of saxatilin was used in each
animal, and animals were divided into the following four groups
with five mice in each group: 1) bolus injection of total dose (5
mg/kg) at 10 minutes after occlusion; 2) double bolus injection
of saxatilin with a half dose (2.5 mg/kg) of saxatilin at 10
minutes after occlusion and 60 minutes after the first bolus
injection; 3) half-dose bolus injection (2.5 mg/kg) at 10 minutes
after occlusion, then continuous infusion for 60 minutes of the
remaining dose; or 4) bolus injection of 10% of the total dose
(0.5 mg/kg) at 10 minutes after occlusion, and then continuous
infusion of the remaining dose (4.5 mg/kg) for 60 minutes.
Assessment of recanalization
The presence and degree of recanalization were assessed
by measuring blood flow. Immediately after 2 hours of blood-
flow monitoring, the CCA was removed from all mice, fixed with
4% paraformaldehyde solution, and embedded in paraffin for
histological examination. Paraffin blocks were consecutively
sectioned in a transverse direction into 3 μm slices, mounted
on glass slides, and stained with hematoxylin and eosin.
Dose response to saxatilin.  Carotid blood flow was
determined by calculating the area under time-flow curves. All
measured values were standardized by the minimum blood
flow of each animal to avoid differences from variations in
physiological condition between animals. Thrombolytic effects
were calculated as described below and expressed as percent
of mean control baseline blood flow: (mean blood flow during 2
hours of monitoring/mean baseline blood flow) × 100. Mean
values of each group in the dose-response study were
calculated and graphed on a standard thrombolytic activity
curve (mean ± SD).
Thrombolytic effects over time.  Average blood flow was
calculated for each animal each minute to achieve a
representative time-dependent pattern during monitoring.
Values for mean and standard deviation of all animals in each
group were calculated, and temporal changes are shown as
continuous bar graphs.
Time to recanalization.  Time from administration of
saxatilin to effective recanalization was assessed. Effective
recanalization was defined as restoration of blood flow to at
least 50% of the baseline level, maintained for longer than 30
minutes.
Mechanism of action of saxatilin
Inhibition on platelet aggregation using platelet
aggregometry.  Blood (900 μl) was drawn by cardiac puncture
from five mice anesthetized with isoflurane into a syringe
containing 100 μl of 150 USP sodium heparin solution,
resulting in a final heparin concentration of 15 USP/ml. A total
of 500 μl of heparinized whole blood was mixed with the same
volume of normal saline. Saxatilin concentrations were
adjusted by dilution with normal saline, and 0.1, 1, or 2 μg of
saxatilin against adenosine diphosphate (ADP) and 5, 50, or
100 μg of saxatilin against collagen were added into each test
cuvette and preincubated with magnetic stirring at 37°C for 5
minutes. The same volume of normal saline was added as a
control. Agonists for platelet aggregometry were 20 µM ADP or
5 μg/ml of collagen (Chronolog Corporation, Havertown, PA).
Platelet aggregation activity was measured with an impedance
method in a platelet aggregometer (Chronolog 700; Chronolog
Corporation, Havertown, PA).
Disaggregation of preformed platelet aggregated.  To test
saxatilin effects on preformed platelet aggregates, 10, 50, and
250 μg of saxatilin or the same volume of normal saline as a
control were added to cuvettes after maximal aggregation in
response to 20 μM ADP or 5 μg/ml of collagen. Platelet
disaggregation effects were calculated as percentage of
restoration to baseline levels.
Fibrin/fibrinogen zymography.  Fibrin/fibrinogen
zymography was performed to determine fibrinolytic activity.
Fibrinogen gels were prepared using 12% sodium dodecyl
sulfate (SDS)-polyacrylamide gels containing 1.2% fibrinogen
(Hyphen Biomed, Neuville-sur-Oise, France) and 0.1 NIH
unit/ml of thrombin (Hyphen Biomed, Neuville-sur-Oise,
France). A total of 100 μg saxatilin or 3 ng rt-PA (Actilyse;
Boehringer Ingelheim, Ingelheim, Germany) with an equal
volume of sample buffer (80 mM Tris-HCl, pH 6.8, 4% SDS,
10% glycerol, 0.01% bromophenol blue) was loaded into wells.
Gels were rinsed in 150 ml of 2.5% Triton X-100 (15 minutes)
and incubated with 250 ml reaction buffer (30 mM Tris, pH 7.4,
200 mM NaCl2, and 0.02% NaN3) for 12 hours at 37°C. Gels
were stained with 0.1% amido black containing acetic acid,
methanol, and distilled water (volume ratio 1:3:6) for 1 hour and
destained by four washes with the same solution without amido
black for 130 minutes. Gels were scanned using a flatbed
scanner (ArtixScan F1; Microtek International Inc., Hsinchu,
Taiwan) [25,27].
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Binding affinity test for integrin receptors.  To investigate
the interaction of saxatilin with integrins, Fc-tagged
recombinant protein was generated because there was no
available antibody against saxatilin. The vector encoded the Fc
region of human IgG1 (~230 amino acids). Interaction with
integrins was evaluated using enzyme-linked immunosorbent
assay (ELISA). Integrins for α2bβ3, αvβ3, α5β1, αvβ1, αvβ5, α1β1,
and α2β1 (7148-A2, 3050-AV, 3230-A5, 6579-AV, 2528-AV,
7064-AB, and 5698-A2; R&D Systems, Minneapolis, MN, USA)
(100 ng) were immobilized in 96-well immunoplates for 16
hours at 4°C. Each well was blocked with skim milk and
washed three times with 0.05% PBS-T. Saxatilin-Fc (~100 nM)
was added to wells and incubated for 2 hours at room
temperature. After washing three times with PBS-T, anti-HuFc
antibody conjugated to HRP (31413; Thermo Fisher Scientific
Inc., Rockford, IL, USA) (1:2000) was added to wells and
incubated for 1 hour at room temperature. Nonadherent
antibodies were removed by washing three times with PBS-T.
Substrate was o-phenylenediamine tablets solubilized in
phosphatidylcholine buffer; 100 μl was added to each well and
incubated for 10 minutes. Absorbance at 490 nm was read on
a spectrophotometer. We determined the Kd values from the
titration curve using the simple linearization method [28]. We
can read relative saturation value (i) from the titration curve.
According to the modified linearization method [29], the plot of
1/(1 - i) vs ligand concentration/i gives a straight line and
evaluates the apparent dissociation constant. The slope of the
plot is 1/Kd.
Comparison of thrombolytic effects of agents
We evaluated thrombolytic effects of other well-known
plasminogen activators: rt-PA (Actilyse; Boehringer Ingelheim,
Ingelheim, Germany), urokinase-type PA (u-PA) (Urokinase;
Green Cross Corp., Yongin, Korea), and the GP IIb/IIIa
receptor antagonists abciximab (ReoPro; Lilly Pharma
Production GmbH & Co., Hamburg, Germany) and tirofiban
(Aggrastat; Iroko Cardio Australia Pty Ltd, Sydney, Australia).
Agents were administrated as 10% IV bolus injection with
continuous infusion of the remaining 90% for 1 hour at 0.9, 1.8,
2.7, 4.8, 7.2, 9, or 18 mg/kg for rt-PA; 100, 500, 1000, 5000,
10,000, or 50,000 IU/kg for u-PA; 0.25, 0.5, 1, 2.5, 5, 10, 20, or
40 mg/kg for abciximab; and 0.5, 1.25, 2.5, 3.75, 5, or 10
mg/kg for tirofiban. An equal volume of normal saline was
administered to control animals.
Half-life measurement of saxatilin in mice
To evaluate half-life of saxatilin in vivo, 8-week-old male ICR
mice (31-36 g) were used. Saxatilin was conjugated with NHS-
Rhodamine (Thermo Fisher Scientific Inc., Rockford, IL, USA)
according to manufacturer’s instruction. NHS-Rhodamine was
dissolved in 10 mg/ml of dimethylsulfoxide (Sigma-Aldrich Inc.,
St. Louis, MO, USA). Saxatilin and NHS-Rhodamine were
mixed and incubated at room temperature for 1 hour, and then
non-reacted NHS-Rhodamine was removed with PD-10
Desalting Columns (GE Healthcare Bio-Sciences Corp.,
Piscataway, NJ, USA). Rhodamine-labeled saxatilin was
diluted in 0.5 mg/ml and was administered intravenously at 5
mg/kg. To isolate serum, blood was collected from the jugular
vein at 0, 5, 10, 20, 40, and 80 minutes after administration of
Rhodamine-labeled saxatilin. The blood was incubated at room
temperature for 30 minutes in dark and serum was separated
by centrifugation at 10,000 rpm for 10 minutes. The serum was
placed in black 96-well microplate (Thermo Fisher Scientific
Inc., Rockford, IL, USA). Fluorescence was acquired via LS
50B Fluorescence Spectrometer (PerkinElmer, Waltham, MA,
USA).
Thrombolytic effects on aged thrombus
Thrombosis was induced in the same manner as it was
performed in the dose-response study. To avoid spontaneous
recanalization, distal site of the CCA was ligated with Silkam
5-0 thread (Silkam, B Braun Aesculap, Tuttlingen, Germany)
immediately after achieving complete occlusion. After 1, 3, 6,
12, or 24 hours, the CCA ligation was gently removed and then
5 mg/kg saxatilin was administered intravenously (10% bolus
and then continuous infusion of the remaining dose for 60
minutes). Thrombus at a time of complete occlusion was used
as control fresh thrombus. Randomly selected five mice were
used in each group. To compare thrombolytic efficacy between
saxatilin and rt-PA on aged thrombus, 9 mg/kg rt-PA was
administered in the same way at 3 or 6 hours after complete
occlusion.
Safety assessment
Hematological assessment.  To assess whether saxatilin
administration causes thrombocytopenia or neutropenia,
hematologic analyses were performed with blood collected
from 5 mice after sham operation. Immediately after infusion of
5 mg/kg saxatilin or same volume of normal saline for 60
minutes, 1 ml of blood was collected in 10% EDTA via the
lateral saphenous vein. Complete blood count (CBC) with
differential counts was obtained using the automatic cell
counter (MS9-5V; Melet Schloesing Laboratories, Cergy-
Pontoise, France).
Bleeding time assays.  Randomly selected four mice were
used in each group. Immediately after infusion of 5 mg/kg
saxatilin or same volume of normal saline for 60 minutes,
bleeding time was assessed by transection of the tail at 1 cm
from the tail tip using a sharp scalpel. Blood was blotted every
15 seconds and the time period from tail transection to
cessation of bleeding was defined as the bleeding time.
Bleeding times exceeding 600 seconds were considered as
600 seconds.
Statistical analysis
Statistical analyses were performed using SPSS (version
20.0, SPSS Inc., Chicago, IL, USA). Normality of distributions
was verified using the Kolmogorov-Smirnov test. Differences
among groups in dose response studies were compared with a
one-way ANOVA test, followed by a post-hoc Tukey method.
Differences between groups in hematological assessment were
compared with a Mann-Whitney U test. Values were presented
as a mean ± standard deviation (SD). P < 0.05 was considered
significant.
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Results
Arterial response to various FeCl3 concentrations
No complete occlusion was observed by 10% or 20% FeCl3.
Two of the five mice by 30% and all of the five mice by 40%
achieved complete occlusion, but all of them showed
spontaneous recanalization during monitoring for 150 minutes
except one mouse by 40%. All mice by 50% FeCl3 achieved
complete occlusion, which was maintained without
spontaneous recanalization during the monitoring (Figure 1).
Therefore, 50% FeCl3 was used for the remaining experiments.
Consistency of the animal model
After 5 minutes of FeCl3, CCA blood flow was rapidly and
consistently reduced to nearly zero in all five animals examined
(Figure 2A). CCA thrombotic occlusion was demonstrated by
histologic examination (Figure 2B). Thrombus sizes were
similar among the animals (length: 1.139 ± 0.091 mm; area:
0.305 ± 0.055 mm2).
Electron microscope features of the carotid artery and
thrombus after FeCl3
The regions farthest from where FeCl3 was applied showed
relatively normal vascular structure, with normally shaped
endothelial cells, smooth muscle cells, erythrocytes, and
discoid platelets (Figures 2Ca, Da). Endothelial cells appeared
empty with a loss of organelles. Some platelets were activated
and aggregated and adhered to the luminal surface in mildly
damaged regions (Figures 2Cb, Db). At the thrombus border,
activated and aggregated platelets adhered to the damaged
luminal surface, and no intact endothelial cells were observed
(Figures 2Cc, Dc). In severely damaged regions, platelet-rich
thrombi containing erythrocytes completely occluded the
vascular lumen (Figures 2Cd, Dd). FeCl3 treatment caused a
loss of vascular undulation with a flattened and disconnected
Figure 1.  Arterial response to various concentrations (10-50%) of FeCl3.  A: mean values of all animals in a group were
calculated. Temporal changes are shown as continuous bar graphs (mean ± SD). B: Time-flow curves of all mice in each group. All
mice by 50% FeCl3 achieved complete occlusion, which was maintained without spontaneous recanalization during period for 150
minutes of monitoring.
doi: 10.1371/journal.pone.0081165.g001
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arrangement of smooth muscle cells. The internal elastic
lamina remained intact even in severely damaged regions.
Dose-dependent thrombolytic effects of saxatilin
Saxatilin treatment did not cause any notable changes in
blood flow at a dose of 1 mg/kg (2.36 ± 0.78%) or 1.75 mg/kg
(5.14 ± 2.92%) compared to the normal saline group (2.42 ±
1.07%) (Figure 3A, 9A). Blood flow was restored at 2.5 mg/kg
(32.50 ± 33.70%) and increased in a dose-dependent manner.
At 3.75 mg/kg saxatilin, blood flow was significantly increased
compared to the normal saline control (60.50 ± 38.78%, p =
0.019), and 5 mg/kg restored blood flow to nearly baseline
levels (94.50 ± 20.47%). No significant differences were
observed between 5 and 10 mg/kg of saxatilin (94.94 ±
39.05%, p > 0.999).
Figure 2.  Reliability of the FeCl3-induced arterial thrombosis model.  A: Blood flow was monitored using an ultrasonic Doppler
ﬂow meter in the carotid artery. Representative time-flow curve from FeCl3-induced arterial thrombosis. Complete occlusion was
defined as absence of blood flow for 10 minutes. B: Hematoxylin and eosin staining of the carotid artery with thrombotic occlusion
after FeCl3 treatment. Original magnification ×100. C: Transmission electron microscopy. D: Scanning electron microscopy. Boxes in
Figure 2B indicate sites of electron microscopy images. a) Region farthest from the site of FeCl3 application with intact vascular
structure and normally shaped erythrocytes and discoid platelets. b) Mildly damaged region. Empty endothelial cells with loss of
organelles, activated and aggregated platelets, and platelets adhering to the luminal surface. c) Thrombus border region with no
intact endothelial cells. Activated and aggregated platelets firmly adhered to the damaged region of the luminal surface. d) Severely
damaged region with artery completely occluded by a platelet-rich thrombus containing several erythrocytes. FeCl3-induced damage
caused loss of vascular undulation, but the internal elastic lamina was intact even in the severely damaged region. R: erythrocyte,
P: platelet, E: endothelial cell, SMC: smooth muscle cell, IEL: internal elastic lamina. Original magnification ×2,000 (TEM), ×5,000
(SEM).
doi: 10.1371/journal.pone.0081165.g002
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Figure 3.  Dose-dependent thrombolytic effects of saxatilin (A) and rt-PA (B).  a) Mean values of all animals in a group were
calculated. Temporal changes are shown as continuous bar graphs (mean ± SD). b) Time-flow curves of all mice in each group. As
the dose of saxatilin or rt-PA increases, the time to recanalization and the frequency of reocclusion decreases. Saxatilin showed
relatively short time to recanalization and low frequency of reocclusion compared with rt-PA.
doi: 10.1371/journal.pone.0081165.g003
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Effect of saxatilin by method of administration
Half-life of saxatilin, which was measured using saxatilin
labeled with NHS-Rhodamine, was 4.1 minutes (Figure 4).
Saxatilin at 5 mg/kg was effective in dose-response studies,
so this dosage was used to determine the optimal method of
intravenous administration of saxatilin (Figure 5). Mean
percentages of blood flow compared to baseline blood flow
were 77.01 ± 46.11% in a group that received saxatilin by a
bolus injection of the total dose; 85.23 ± 29.95% in a group that
received a double bolus injection with half of a dose; 80.72 ±
30.13% in a group that received a half-dose bolus injection with
continuous infusion of the remaining dose; and 94.50 ± 20.47%
in a group that received a bolus injection of 10% of the total
dose with continuous infusion of the remaining dose.
Decreased thrombolytic effects were observed at different
times according to administration method. Abrupt reocclusion
was observed approximately 50 minutes after the first bolus
injection in mice treated with double bolus injection,
approximately 100 minutes after a total dose bolus injection,
and approximately 110 minutes after a half-dose bolus injection
with continuous infusion of the remaining half dose.
Reocclusion was not observed with a bolus injection of 10% of
the total dose and continuous infusion of the remaining dose
(Figure 5).
Time to effective recanalization by saxatilin
Effective recanalization was not observed in mice treated
with normal saline, 1 mg/kg saxatilin, or 1.75 mg/kg saxatilin.
Only two of five mice treated with 2.5 mg/kg of saxatilin and
three of five mice treated with 3.75 mg/kg of saxatilin showed
effective recanalization. Effective recanalization was observed
in all mice treated with saxatilin at 5 or 10 mg/kg (Figure 6A).
The time to effective recanalization was 32.92 ± 23.52 minutes
Figure 4.  Half-life of saxatilin in mice.  Fluorescence was
measured from sera isolated at the indicated time-points (0, 5,
10, 20, 40, or 80 minutes) after administration of Rhodamine-
labeled saxatilin. Half-life of saxatilin was 4.1 minutes in mice.
Values are presented as a mean ± standard deviation.
doi: 10.1371/journal.pone.0081165.g004
in mice treated with 2.5 mg/kg saxatilin, 21.75 ± 21.62 minutes
in mice treated with 3.75 mg/kg, 13.92 ± 6.02 min in mice
treated with 5 mg/kg, and 19.46 ± 19.75 minutes in mice
treated with 10 mg/kg of saxatilin (Figure 6A).
Effective recanalization was also evaluated according to
saxatilin administration method. All mice treated with 5 mg/kg
saxatilin achieved effective recanalization except for two mice
administered a bolus injection of the total dose. Time to
effective recanalization was 2.86 ± 0.22 minutes in mice
treated with a bolus injection of the total dose, 13.44 ± 26.31
minutes in mice that received a double bolus injection, 19.48 ±
25.94 minutes in mice that received a half-dose bolus injection
followed by continuous infusion of the other half dose, and
13.92 ± 6.02 minutes in mice treated with a bolus injection of
10% of the total dose with continuous infusion of the remaining
dose (Figure 6B).
Effects of saxatilin on platelet aggregation
Platelet aggregometry showed that saxatilin has a strong
inhibitory effect on platelet aggregation (Figure 7A). Saxatilin
inhibited 50% of platelet aggregation at 0.1 μg/ml (8 ohms),
87.5% at 1 μg/ml (7 ohms), and 100% at 2 μg/ml (0 ohm) in
response to 20 μM ADP (maximal control aggregation was 16
ohms) (Figure 7Aa). Saxatilin inhibited 63.64% of platelet
aggregation at 5 μg/ml (8 ohms), 90.91% at 50 μg/ml (2 ohms),
and 95.45% at 100 μg/ml (1 ohm) in response to 5 μg/ml
collagen (maximal control aggregation was 22 ohms) (Figure
7Ab).
Experiments using preformed thrombi showed dose-
dependent disaggregating effects of saxatilin (Figure 7B). ADP-
induced platelet aggregates were resolved rapidly. At 14
seconds after addition, impedance was restored by 15.79% at
10 μg/ml, 48% at 50 μg/ml, and to basal levels (100%) at 250
μg/ml saxatilin (Figure 7Ba). The response to the collagen-
induced platelet aggregates was relatively slow. At 300
seconds after addition, impedance was restored by 10.32% at
10 μg/ml, by 20% at 50 μg/ml, and by 31.58% at 250 μg/ml
saxatilin (Figure 7Bb).
Fibrinolytic effect of saxatilin
Both fibrin and fibrinogen zymograms showed clear bands of
rt-PA. However, saxatilin did not demonstrate a clear
fibrinolysis band, which suggested that saxatilin had no
fibrinolytic activity (Figure 7C).
Integrin binding assay
We investigated the binding affinity of saxatilin-Fc to various
integrins (Figure 8). Saxatilin-Fc bound to integrin α2bβ3 with the
highest affinity (Kd = 6.8 × 10-12 M). Saxatilin-Fc also showed
high affinity for integrins αvβ3 (Kd = 2.0 × 10-11 M), αvβ5 (Kd = 3.5
× 10-9 M), α5β1 (Kd = 4.4 × 10-9 M), and αvβ1 (Kd = 5.9 × 10-9 M).
Saxatilin-Fc did not bind to integrins α1β1 or α2β1.
Dose-dependent thrombolytic effects of rt-PA, u-PA,
abciximab, and tirofiban
Dose-dependent effects of thrombolytic agents were
determined by calculating the area under time-flow curves
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(Figure 9). After rt-PA administration (Figure 3B, 9B), blood
flow restoration increased in a dose-dependent manner and
was significant at 7.2 mg/kg (54.45 ± 21.68%, p = 0.001)
compared to the normal saline group (2.42 ± 1.07%). Blood
flow was restored to nearly baseline levels at 9 mg/kg (80.52 ±
20.16%) and 18 mg/kg (92.44 ± 27.27%) of rt-PA. In contrast to
Figure 5.  Thrombolytic effect of saxatilin according to administration method.  A: Blood flow patterns after saxatilin. Abrupt
reocclusion in mice after bolus injection of total dose or 50% of total dose. No reocclusion with bolus injection of 10% total dose with
continuous infusion of remaining dose. B: Time-flow curves of all mice in each group. b, bolus injection; i, continuous infusion.
Arrows indicate reocclusion development.
doi: 10.1371/journal.pone.0081165.g005
Figure 6.  Time to effective recanalization.  Effective recanalization was defined as restoration of blood flow to at least 50% of
baseline levels, maintained for longer than 30 minutes. A: Time to effective recanalization by administration dose. No effective
recanalization at 0, 1, or 1.75 mg/kg. Two mice in the 2.5 mg/kg and three mice in the 3.75 mg/kg groups and mice with 5 or 10
mg/kg showed effective recanalization. B: Time to effective recanalization by administration method. All mice except two
administered a bolus injection of the total dose showed effective recanalization. b, bolus injection; i, continuous infusion.
doi: 10.1371/journal.pone.0081165.g006
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rt-PA, the restoration of blood flow was about 35% of baseline
after administration of u-PA (34.96 ± 25.74% at 10,000 IU/kg,
and 35.68 ± 19.54% at 50,000 IU/kg) (Figure 9C). For
abciximab, blood flow restoration was observed at 5 mg/kg
(16.32 ± 8.52%), and increased in a dose-dependent manner.
Blood flow restoration was significant compared to the normal
saline group and maximal at 20 mg/kg (60.19 ± 42.78%, p =
0.002) (Figure 9D). After administration of tirofiban, blood flow
restoration was significant compared to the normal saline group
and maximal at a dose of 10 mg/kg (52.47 ± 16.36%, p <
0.001) (Figure 9E).
Thrombolytic effects on the aged thrombus
Mean percentages of blood flow compared to baseline blood
flow were 94.50 ± 20.47% in the group that received 5 mg/kg
saxatilin at 1 hour; 17.71 ± 27.27% at 3 hours; 4.48 ± 1.37% at
6 hours; 10.67 ± 6.06% at 12 hours; and 4.51 ± 3.04% at 24
hours (Figure 10A). Mean percentages of blood flow compared
to baseline blood flow were 14.26 ± 17.38% in a group that
Figure 7.  Mechanism of thrombus dissolution by saxatilin.  A: Inhibitory effect of platelet aggregation by saxatilin. a) Inhibition
in response to 20 μM ADP or b) 5 μg/ml collagen. Platelet aggregometry shows dose-dependent inhibition of platelet aggregation.
B: Effect of saxatilin on platelet disaggregation. a) Saxatilin effect on a preformed thrombus induced by 20 μM ADP, or b) 5 μg/ml
collagen. Graphs show dose-dependent disaggregation by saxatilin on the preformed thrombus. C: Fibrin/fibrinogen zymography
with rt-PA bands. No band was seen after saxatilin loading.
doi: 10.1371/journal.pone.0081165.g007
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Figure 8.  Binding affinity of saxatilin-Fc for integrins α2bβ3 (A), αvβ3 (B), αvβ5 (C), α5β1 (D), and αvβ1 (E).  a) Titration curves
obtained from ELISA. The relative titration, i, is displayed as the function of saxatilin-Fc concentration. b) Plot of data (a) according
to equation 1/(1 - i) = (saxatilin-Fc concentration/i)/(Kd) - b. The parameter of the straight line, the slope (1/Kd) is shown in the figure.
doi: 10.1371/journal.pone.0081165.g008
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received 9 mg/kg rt-PA at 3 hours and 6.69 ± 1.66% at 6 hours
(Figure 10B).
Safety assessment
Mortality and bleeding after saxatilin
treatment.  Thrombolytic effects of saxatilin were evaluated
using 71 animals. Two animals had bleeding at the cervical
incision site, and one died of bleeding approximately 90
minutes after a bolus injection of saxatilin. The two animals
with bleeding complications had received a single bolus dose
of 5 mg/kg. None of the mice in the other groups showed
bleeding complications.
Hematologic assessment and bleeding time.  No
significant differences in hematologic parameters were
observed between normal saline-infusion group and 5 mg/kg
saxatilin-infusion group (Table 1). The tail bleeding time of
Figure 9.  Dose-dependent thrombolytic effects of thrombolytic agents.  Dose-response curves of saxatilin (A), rt-PA (B), u-PA
(C), abciximab (D), and tirofiban (E). Saxatilin showed no notable changes until 1.75 mg/kg. Blood flow restored at 2.5 mg/kg,
increased dose dependently, was significant at 3.75 mg/kg (p = 0.019), and was nearly baseline at 5 mg/kg; 5 vs. 10 mg/kg saxatilin
(p > 0.999). Blood flow restoration was significant at rt-PA 7.2 mg/kg (54.45 ± 21.68%, p = 0.001), u-PA 10,000 IU/kg (34.96 ±
25.74%, p = 0.049), abciximab 20 mg/kg (60.19 ± 42.78%, p = 0.002), and tirofiban 10 mg/kg (52.47 ± 16.36%, p < 0.001).
doi: 10.1371/journal.pone.0081165.g009
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Figure 10.  Thrombolytic effects of saxatilin (A) and rt-PA (B) on the aged thrombus.  a) Mean values of all animals in a group
were calculated. Temporal changes are shown as continuous bar graphs (mean ± SD). b) Time-flow curves of all mice in each
group. As the thrombus age increases, the thrombolytic effect decreases.
doi: 10.1371/journal.pone.0081165.g010
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normal saline-infusion group was 146.25 ± 14.36 seconds. All 5
mg/kg saxatilin-infused mice showed prolonged bleeding times
exceeding 600 seconds.
Discussion
We demonstrated that saxatilin has strong thrombolytic
effects in vivo and in vitro. The thrombolytic effects of saxatilin
were dose dependent. Time to recanalization decreased with
increasing saxatilin dosage. Reponses to saxatilin varied with
administration method. Administration of the total dose in a
bolus resulted in fast effective recanalization (approximately 3
minutes). However, reocclusion was frequently observed, and
was also observed in mice treated with a bolus injection of 50%
of the total dose. The regimen of a bolus injection of 10% of the
total dose with continuous infusion of the remaining dose for 60
minutes resulted in a longer time to effective recanalization
than treatment with a high-dose bolus injection. However, this
regimen did not show reocclusion. These findings might result
from the relatively short half-life of saxatilin, which was 4.1
minutes in mice.
The findings of this study indicated that saxatilin had
thrombolytic effects on platelets but not fibrin/fibrinogen.
Saxatilin is an RGD-containing protein. RGD-containing
proteins from snake venom are characterized by strong
conservation of the tripeptide RGD and by disulfide bond
arrangements. These structural features might be critical for
potential inhibition of platelet adhesion/aggregation and
antagonism of integrin-mediated adhesion [30]. In an integrin-
binding assay, saxatilin bound to integrins α2bβ3, αvβ3, α5β1,
αvβ1, and αvβ5, with the highest affinity for α2bβ3. Administration
of GP IIb/IIIa antagonists not only prevents thrombus formation,
but also disaggregates preformed fresh thrombi through
competitive binding with the platelet GP IIb/IIIa receptor to the
RGD domain of fibrin or fibrinogen [11]. Saxatilin lyses clots by
dethrombosis and prevention of rethrombosis, similar to other
GP IIb/IIIa antagonists. Saxatilin might have additive effects on
dethrombosis and antithrombosis by acting against multiple
integrins. α2bβ3 does not act alone in mediating platelet
adhesion/aggregation, but as part of a synergistic, multiple
Table 1. Effects of saxatilin on the hematologic parameters
in mice.
 Control Saxatilin P-value
Red blood cell, ×106/mm3 6.97 ± 1.33 7.23 ± 0.53 0.465
Hemoglobin, g/dl 11.15 ± 0.64 11.70 ± 0.57 0.346
Hematocrit, % 46.20 ± 9.05 43.90 ± 5.37 0.917
Platelet, ×103/mm3 1114.00 ± 121.62 1132.00 ± 52.33 0.917
White blood cell, ×103/mm3 3.41 ± 0.90 1.40 ± 0.40 0.754
Neutrophil, % 12.85 ± 14.35 13.25 ± 12.80 0.465
Lymphocyte, % 80.80 ± 16.55 79.55 ± 15.77 0.465
Monocyte, % 4.70 ± 3.11 4.85 ± 2.90 0.293
Eosinophil, % 0.90 ± 0.85 2.00 ± 0.28 0.917
Basophil, % 0.75 ± 0.07 0.35 ± 0.35 0.112
Values are presented as a mean ± standard deviation.
doi: 10.1371/journal.pone.0081165.t001
integrin-ligand association during platelet adhesion and
aggregation [31]. In addition to α2bβ3, saxatilin showed high
affinity for αvβ3 and α5β1, which mediate platelet function along
with α2bβ3 [32]. Strong platelet adhesion, which is followed by
initial interaction between GP1b and von Willebrand factor, is
mediated by integrins such as α5β1 and α2bβ3 [33]. Integrins
α5β1 and α2bβ3 share a fibrinogen-binding site [34]. Integrin α5β1
is involved in contraction of fibrin clots as well as platelet
adhesion [35]. Integrin αvβ3 is involved in thrombus formation
by adhering not only to ligands for α2bβ3 (i.e., von Willebrand
factor, fibrinogen, fibronectin, vitronectin, osteopontin, and
thrombospondin), but also to collagen [33,36]. Thus, maximal
disaggregation of platelets from fibrinogen and inhibition of
platelet adhesion/aggregation and thrombus growth might be
achieved by blocking the effects of multiple integrins on
platelets. These effects might be associated with the increased
thrombolytic effects in our experiments compared to abciximab
and tirofiban, which are well-known GP IIb/IIIa receptor
antagonists.
Saxatilin appears to be safe because its effective dose was
low and it rarely caused bleeding complications. In addition,
saxatilin did not cause any notable changes in hematological
parameters including platelet and neutrophil counts compared
with control group. The most efficient dose in our study (5
mg/kg) was much lower than the known LD50 of saxatilin (400
mg/kg) in ICR mice [26]. In tail bleeding assays, 5 mg/kg
saxatilin prolonged bleeding times. However, among the 71
mice in this study that received saxatilin for evaluation of
thrombolytic effects by various dosage, administering methods,
and thrombus ages, only two bled at the cervical incision site.
These two mice received a single bolus of 5 mg/kg, the highest
quantity administered in a single dose; no bleeding was
observed in other mice, including those receiving a 10% bolus
injection with continuous infusion of the remaining 90%, which
was most effective. A previous report demonstrated that an
increase in vascular permeability induced by vascular
endothelial growth factor was inhibited by monoclonal
antibodies that block integrin αvβ5 [37]. Saxatilin showed high
affinity for integrin αvβ5 in our study; thus, saxatilin might be
beneficial as an αvβ5 antagonist for preventing bleeding
complications induced by vascular leakage. Additionally, αvβ5
inhibition following administration of saxatilin might be
advantageous for stroke outcomes. In β5-deficient mice,
infarction volume and blood-brain barrier breakdown is
dramatically reduced after permanent middle cerebral artery
occlusion [37].
We also determined the effect of saxatilin on aged thrombus.
Thrombolytic effects of saxatilin decreased as thrombus age
increased. Decreased thrombolytic effects in aged thrombi
were also seen in rt-PA. While effects of thrombolytic drugs on
aged thrombi have not well known, our findings suggest that
effects of drugs acting on platelets as well as fibrinogen may be
decreased as thrombus age increases and that reducing time
from onset to treatment is important to enhance effects of the
thrombolytic drugs.
Our methods had distinct features compared to other
experimental models evaluating thrombolytic effects. First, to
produce arterial thrombosis, we used a smaller filter paper
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saturated with a higher concentration (50%) of FeCl3 than
previous studies (2.5–65%) [23,24,38,39]. This was because
we needed to monitor blood flow for a longer period to examine
the thrombolytic effects of drugs. In addition, the smaller
thrombi produced from smaller filter papers were better for
monitoring blood flow, examining pathology after drug
treatment, and determining drug-induced thrombolytic effects.
When we used low concentrations of FeCl3 such as 10-40%,
blood flow restored spontaneously during 150 minutes of
monitoring period after initially complete occlusion. Low
concentrations of FeCl3 are usually used to evaluate
thrombosis mechanisms or the effects of antithrombotic drugs,
which do not require the long-term monitoring needed to
evaluate thrombolytic effects. Scanning and transmission
electron microscopy showed that 50% FeCl3 causes a loss of
undulation and severe damage to the endothelium and smooth
muscle but did not damage internal elastic lamina. These
findings were consistent with previous observations using a
lower dose of FeCl3 (7.5-20%) [38].
Second, the assessment methods we used were different
from previous studies in which recanalization is typically
assessed to determine thrombolytic effects. Our study
determined and calculated the degree of flow restoration on a
minute-by-minute basis using ultrasound blood flow
measurements. Histological examination showed that blood
flow measurements were a good representation of the degree
of recanalization and thrombus resolution. The assessment
method we used provided quantitative data on degree of
recanalization, time to effective recanalization, and real-time
occurrence of reocclusion. Our method also enabled group
comparisons as well as quantitative data on each animal. We
found a dose-dependent thrombolytic effect for rt-PA. The
effective dose of rt-PA in rodents is about 10-fold higher than
for humans because of different PA systems [40-42].
Therefore, 9 mg/kg, which gave optimal thrombolytic effects in
mice in our study, is comparable to 0.9 mg/kg in humans. Thus,
this assessment method might be a reliable tool for evaluating
the in vivo efficacy of new thrombolytic drugs.
Third, thrombolytic effects were determined using platelet
aggregometry. Platelet aggregometry has been used to test
inhibition of thrombus formation and is typically used to assess
platelet anti-aggregating drugs. However, we used platelet
aggregometry to assess platelet disaggregation after
administering a thrombolytic drug to preformed thrombi. We
found that platelet aggregometry could also be used to assess
in vitro thrombolytic effects.
In conclusion, disaggregation of platelets from fibrin is a
potential approach to dissolving thrombi [11,12]. Several
specific GP IIb/IIIa receptor inhibitors have been developed
and are currently clinically available. However, saxatilin, which
originates from natural sources and inhibits multiple integrins
that act on platelets, could be a candidate for a new
thrombolytic drug with improved potency.
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